| 000 | 01826 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515084912.0 | ||
| 264 | 0 | _c20071213 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1705826 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aResnick, I B | |
| 245 | 0 | 0 |
_aAllogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cNov 2007 |
||
| 300 |
_a957-64 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xtherapeutic use |
| 650 | 0 | 4 |
_aBusulfan _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xetiology |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xprevention & control |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aTransplantation Chimera _ximmunology |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 |
_aVidarabine _xanalogs & derivatives |
| 650 | 0 | 4 |
_abeta-Thalassemia _xtherapy |
| 700 | 1 | _aAker, M | |
| 700 | 1 | _aTsirigotis, P | |
| 700 | 1 | _aShapira, M Y | |
| 700 | 1 | _aAbdul-Hai, A | |
| 700 | 1 | _aBitan, M | |
| 700 | 1 | _aGesundheit, B | |
| 700 | 1 | _aAmar, A | |
| 700 | 1 | _aAckerstein, A | |
| 700 | 1 | _aSamuel, S | |
| 700 | 1 | _aSlavin, S | |
| 700 | 1 | _aOr, R | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 40 _gno. 10 _gp. 957-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1705826 _zAvailable from publisher's website |
| 999 |
_c17374449 _d17374449 |
||